Pharma pipelines don’t fail in the lab—they fail in the courtroom.
That’s the uncomfortable truth behind Freedom-to-Operate (FTO). One overlooked patent, one misread claim, one “minor” jurisdictional nuance—and suddenly your launch timeline is no lon…

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Copying” Into Defensibility
In generic drug land, the default playbook is familiar: file an ANDA, ride the reference product’s data, and compete on price. But that strategy has a ceiling—and it’s get…

Pharma IP teams are used to thinking in timelines: filing dates, priority windows, prosecution milestones, and—eventually—patent expiry. But in Russia, the “clock” can move in ways that are easy to miss until it’s too late.
Here’s the agitation: if you…

Litigation-Aware Prosecution: Turn Your Drug Patent Portfolio Into a Competitive Assertion Asset
In pharma, patents are often treated like insurance—something you buy for the day a competitor files a challenge. But the real competitive advantage comes …

Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical market, timing is everything. Patent cliffs don’t just change drug prices; they reshape formularies, bargaining power, and the entire economics of ca…

Generic launches don’t “just happen.” They arrive on a calendar that’s been quietly negotiated—by patents, exclusivities, litigation, regulatory strategy, and timing games that only become obvious in hindsight.
If you’re still forecasting generic drug …

Pharma’s “hidden talent” isn’t in the lab—it’s in the Orange Book.
Most people think the FDA Orange Book is just a regulatory filing: a list of approved drugs, patents, and exclusivities. But if you’re trying to find who is actually building defensib…

Biotech investors love a good story. But portfolio winners are usually built on something less glamorous: how you rank risk, timing, and value across a pipeline.
That’s where two metrics—Net Present Value (NPV) and the Profitability Index (PI)—move fro…

The Patent Cliff Isn’t Just a Pharma Problem—It’s a Talent Problem.
If you work in biopharma, you’ve probably heard the phrase “patent cliff” used like a weather forecast: inevitable, looming, and disruptive. But here’s the uncomfortable truth—what’s h…

Stop Overstocking: How Patent Intelligence Helps Wholesalers Reduce Branded Drug Inventory Risk
Branded drug inventory is a balancing act—until patent cliffs turn it into a gamble.
For wholesalers, the risk isn’t theoretical. It’s operational, financia…